SCSukantha Chandrasekaran

Sukantha Chandrasekaran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sukantha Chandrasekaran has a total of 181 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Discrepancy between reference phenotypic and genotypic detection of cphA metallo-β-lactamase in Aeromonas spp.

    by Benjamin von Bredow, Marisol Trejo, Kevin W. Ward, Kevin P. Trieu, Cynthia A. Santellan, Omai B. Garner, Shangxin Yang, Sukantha Chandrasekaran

    Infection with Aeromonas spp. can be difficult to treat due to the common presence of multiple β-lactamase genes. Although the presence of β-lactamase genes appears to be mostly species-specific, species-level identification of Aeromonas spp. is currently unreliable. Routine phenotypic susceptibility testing is unreliable for the detection of chromosomal cphA metallo-β-lactamase-mediated carbapenem resistance, which can lead to adverse outcomes. A reliable, easy-to-use phenotypic method for the detection of carbapenem resistance in Aeromonas spp. would allow laboratories to better guide treatment of these organisms. This study used whole-genome sequencing for the detection of β-lactamase genes in 43 Aeromonas spp. isolates as a reference to evaluate different phenotypic methods for the detection of cphA . Standard Kirby Bauer disk diffusion (KB) and broth microdilution (BMD) were least sensitive, detecting carbapenem resistance in 3 to 5 of 24 cphA -positive isolates, depending on the drug and method. Increased-inoculum KB detected resistance in 3 to 14 of 24 isolates, whereas increased-inoculum BMD detected resistance in 11 to 18 of 24 isolates depending on the carbapenem. The modified carbapenem inactivation method (mCIM) was positive for all 24 isolates, whereas EDTA-modified mCIM was positive for 19/24 isolates. None of the 19 cphA -negative isolates tested positive by mCIM or resistant by any phenotypic method. The mCIM is an easy-to-implement method that detected cphA -mediated carbapenem resistance with 100% sensitivity and specificity and could help guide effective treatment of Aeromonas sp. infection. IMPORTANCE: Serious infections with Aeromonas species are associated with high rates of morbidity and mortality. Some species can have a carbapenemase that is not detectable by typical phenotypic methods. It is important for clinical laboratories to be aware and have a method for identifying and reporting this phenotype. Clinicians should also be aware of this resistance phenotype when choosing an antibiotic for therapy. Here, we show the difficulty in using broth microdilution or disk diffusion to identify carbapenem resistance mediated by a specific carbapenemase, cphA , in Aeromonas spp. Through genotypic analysis, we also found cphA to be associated with certain species of Aeromonas . Unfortunately, identification to the species level using typical methods like MALDI-TOF is also difficult. This study presents data for a previously well-established method, modified carbapenem inactivation method, that can be utilized to reliably detect this resistance phenotype in commonly encountered Aeromonas species.


  • Open Access

    Defining antimicrobial susceptibility testing methods and breakpoints among Achromobacter species

    by Harley Harris, Haley Stambaugh, Emily Jacobs, Amira Bhalodi, Sukantha Chandrasekaran, Nicolynn C. Cole, Jennifer Lu, Tsigereda Tekle, Romney Humphries, Patricia J. Simner

    Achromobacter species can cause opportunistic infections which are difficult to treat due to a variety of antimicrobial resistance (AMR) mechanisms. As such, antimicrobial susceptibility testing (AST) is a cornerstone to successful treatment for these organisms. Currently, there are no specific Clinical and Laboratory Standards Institute (CLSI) AST guidelines for Achromobacter species. The purpose of this study was to (i) establish tentative CLSI M45 MIC and disk diffusion (DD) breakpoints (BPs), (ii) evaluate the modified carbapenem inactivation method (mCIM), and (iii) understand the mechanisms mediating AMR among Achromobacter species. Contemporary MIC data from multiple sources were collated to define the tentative epidemiological cutoff values (tECVs), and the MIC distributions were used to inform the establishment of MIC BPs for various agents. A disk-to-MIC correlate study with 91 isolates from across the United States was completed by testing reference broth microdilution and DD from the same inoculum and applying the dBETS software to establish DD BPs. Lastly, the mCIM and whole-genome sequencing (WGS) were pursued. The tECVs for piperacillin-tazobactam, imipenem, and meropenem were 1, 2, and 0.5 µg/mL, respectively. Disk correlates met CLSI M23 acceptance criteria with a few exceptions related to a small number of isolates, resulting in high minor errors. WGS revealed that 82 (90.1%) isolates harbored a bla OXA variant with bla OXA-114 predominating (90.2%). Nineteen isolates harbored acquired beta-lactamase genes, including 16 bla AXC , 2 bla VIM-4 , and 1 bla AZM-1. The mCIM had a sensitivity of 100% and specificity of 87%. Upon review, the CLSI M45 committee set tentative MIC and DD BPs for piperacillin-tazobactam, imipenem, meropenem, and trimethoprim-sulfamethoxazole. IMPORTANCE: Achromobacter species can cause opportunistic infections which may be difficult to treat due to a variety of antimicrobial resistance mechanisms. Antimicrobial susceptibility testing is a critical component of patient treatment for these infections. Currently, the Clinical and Laboratory Standards Institute M100 non-Enterobacterales susceptibility test interpretive criteria and methodology are utilized for Achromobacter by clinical laboratories and likely do not accurately predict susceptibility results for Achromobacter species. This study was designed to establish tentative MIC and disk diffusion breakpoints specific to Achromobacter species.


  • Top Cited Papers
    Open Access

    Real-world clinical impact of plasma cell-free DNA metagenomic next-generation sequencing assay

    by Ishminder Kaur, Bennett Shaw, Ashrit Multani, Christine Pham, Sanchi Malhotra, Ethan Smith, Kristina Adachi, Paul Allyn, Zackary Bango, Omer Eugene Beaird, et al.

    Objective: To describe the real-world clinical impact of a commercially available plasma cell-free DNA metagenomic next-generation sequencing assay, the Karius test (KT). Methods: We retrospectively evaluated the clinical impact of KT by clinical panel adjudication. Descriptive statistics were used to study associations of diagnostic indications, host characteristics, and KT-generated microbiologic patterns with the clinical impact of KT. Multivariable logistic regression modeling was used to further characterize predictors of higher positive clinical impact. Results: We evaluated 1000 unique clinical cases of KT from 941 patients between January 1, 2017–August 31, 2023. The cohort included adult (70%) and pediatric (30%) patients. The overall clinical impact of KT was positive in 16%, negative in 2%, and no clinical impact in 82% of the cases. Among adult patients, multivariable logistic regression modeling showed that culture-negative endocarditis (OR 2.3; 95% CI, 1.11–4.53; P .022) and concern for fastidious/zoonotic/vector-borne pathogens (OR 2.1; 95% CI, 1.11–3.76; P .019) were associated with positive clinical impact of KT. Host immunocompromised status was not reliably associated with a positive clinical impact of KT (OR 1.03; 95% CI, 0.83–1.29; P .7806). No significant predictors of KT clinical impact were found in pediatric patients. Microbiologic result pattern was also a significant predictor of impact. Conclusions: Our study highlights that despite the positive clinical impact of KT in select situations, most testing results had no clinical impact. We also confirm diagnostic indications where KT may have the highest yield, thereby generating tools for diagnostic stewardship.


  • A simple and sensitive test for Candida auris colonization, surveillance, and infection control suitable for near patient use

    by Sukalyani Banik, Burcu Ozay, Marisol Trejo, YanChun Zhu, Charan Kanna, Cynthia Santellan, Bennett Shaw, Sukantha Chandrasekaran, Sudha Chaturvedi, Lindy Vejar, et al.

    Candida auris is a multidrug-resistant fungal pathogen with a propensity to colonize humans and persist on environmental surfaces. C. auris invasive fungal disease is being increasingly identified in acute and long-term care settings. We have developed a prototype cartridge-based C. auris surveillance assay (CaurisSurV cartridge; “research use only”) that includes integrated sample processing and nucleic acid amplification to detect C. auris from surveillance skin swabs in the GeneXpert instrument and is designed for point-of-care use. The assay limit of detection (LoD) in the skin swab matrix was 10.5 and 14.8 CFU/mL for non-aggregative (AR0388) and aggregative (AR0382) strains of C. auris , respectively. All five known clades of C. auris were detected at 2-3-5× (31.5–52.5 CFU/mL) the LoD. The assay was validated using a total of 85 clinical swab samples banked at two different institutions (University of California Los Angeles, CA and Wadsworth Center, NY). Compared to culture, sensitivity was 96.8% (30/31) and 100% (10/10) in the UCLA and Wadsworth cohorts, respectively, providing a combined sensitivity of 97.5% (40/41), and compared to PCR, the combined sensitivity was 92% (46/50). Specificity was 100% with both clinical ( C. auris negative matrix, N = 31) and analytical (non- C . auris strains, N = 32) samples. An additional blinded study with N = 60 samples from Wadsworth Center, NY yielded 97% (29/30) sensitivity and 100% (28/28) specificity. We have developed a completely integrated, sensitive, specific, and 58-min prototype test, which can be used for routine surveillance of C. auris and might help prevent colonization and outbreaks in acute and chronic healthcare settings. IMPORTANCE: This study has the potential to offer a better solution to healthcare providers at hospitals and long-term care facilities in their ongoing efforts for effective and timely control of Candida auris infection and hence quicker response for any potential future outbreaks.


  • Open Access

    Fungal Whole-Genome Sequencing for Species Identification: From Test Development to Clinical Utilization

    by Zackary Salem-Bango, Travis K Price, June L Chan, Sukantha Chandrasekaran, Omai B Garner, Shangxin Yang

    Using next-generation sequencing (NGS), we developed and validated a whole-genome sequencing (WGS)-based clinical test for fungal species identification on clinical isolates. The identification is mainly based on the fungal ribosomal internal transcribed spacer (ITS) region as the primary marker, and additional marker and genomic analysis applied for species within the Mucorales family (using the 28S rRNA gene) and Aspergillus genus (using the beta-tubulin gene and k-mer tree-based phylogenetic clustering). The validation study involving 74 unique fungal isolates (22 yeasts, 51 molds, and 1 mushroom-forming fungus) showed high accuracy, with 100% (74/74) concordance on the genus-level identifications and 89.2% (66/74) concordance on the species level. The 8 discrepant results were due to either the limitation of conventional morphology-based methodology or taxonomic changes. After one year of implementation in our clinical laboratory, this fungal NGS test was utilized in 29 cases; the majority of them were transplant and cancer patients. We demonstrated the utility of this test by detailing five case studies, in which accurate fungal species identification led to correct diagnosis, treatment adjustment or was ruled out for hospital acquired infection. This study provides a model for validation and implementation of WGS for fungal identification in a complex health system that serves a large immunocompromised patient population.


  • Open Access

    Genetic Predictive Factors for Nonsusceptible Phenotypes and Multidrug Resistance in Expanded-Spectrum Cephalosporin-Resistant Uropathogenic Escherichia coli from a Multicenter Cohort: Insights into the Phenotypic and Genetic Basis of Coresistance

    by Nicole Jackson, Cheyenne R. Belmont, Nicole J. Tarlton, Yuan Hu Allegretti, Sheila Adams-Sapper, Yolanda Yue Huang, Clarissa A. Borges, Bradley W. Frazee, Danka Florence-Petrovic, Clarisse Hufana, et al.

    The rising incidence of resistance to expanded-spectrum cephalosporins among Escherichia coli strains, the most common cause of UTIs, is threatening our ability to successfully empirically treat these infections. ESCR E. coli strains are often MDR; therefore, UTI caused by these organisms often leads to treatment failure, increased length of hospital stay, and severe complications (D. G. Mark, Y.-Y. Hung, Z. Salim, N. J. Tarlton, et al., Ann Emerg Med 78:357–369, 2021, https://doi.org/10.1016/j.annemergmed.2021.01.003 ).


  • Open Access

    Clinical and epidemiological characteristics of SARS-CoV-2 Infection in Los Angeles County youth during the first year of the pandemic

    by Tawny Saleh, Tara Kerin, Trevon Fuller, Sophia Paiola, Mary C. Cambou, Yash Motwani, Caitlin N. Newhouse, Shangxin Yang, Edwin Kamau, Omai B. Garner, et al.


  • Multicenter Evaluation of the Simplexa VZV Direct Assay for Detection of Varicella-Zoster Virus in Cerebrospinal Fluid and Lesion-Swab Specimens

    by P. Pancholi, R. F. Relich, S. Chandrasekaran, J. J. Dunn, P. A. Granato, A. T. Harrington, G. T. Hansen, N. A. Ledeboer, Q. Li, M. D. Sims, et al.

    Varicella-zoster virus (VZV) is the etiologic agent of varicella (chickenpox) and herpes zoster (shingles) infections commonly involving skin, mucous membranes, and less frequently the central nervous system. Traditional methods for the laboratory diagnosis of these infections are time-consuming, labor-intensive, and often insensitive.


  • Open Access

    Genomic epidemiology of the Los Angeles COVID-19 outbreak and the early history of the B.1.43 strain in the USA

    by Longhua Guo, James Boocock, Evann E. Hilt, Sukantha Chandrasekaran, Yi Zhang, Chetan Munugala, Laila Sathe, Noah Alexander, Valerie A. Arboleda, Jonathan Flint, et al.

    Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused global disruption of human health and activity. Being able to trace the early outbreak of SARS-CoV-2 within a locality can inform public health measures and provide insights to contain or prevent viral transmission. Investigation of the transmission history requires efficient sequencing methods and analytic strategies, which can be generally useful in the study of viral outbreaks. Methods: The County of Los Angeles (hereafter, LA County) sustained a large outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To learn about the transmission history, we carried out surveillance viral genome sequencing to determine 142 viral genomes from unique patients seeking care at the University of California, Los Angeles (UCLA) Health System. 86 of these genomes were from samples collected before April 19, 2020. Results: We found that the early outbreak in LA County, as in other international air travel hubs, was seeded by multiple introductions of strains from Asia and Europe. We identified a USA-specific strain, B.1.43, which was found predominantly in California and Washington State. While samples from LA County carried the ancestral B.1.43 genome, viral genomes from neighboring counties in California and from counties in Washington State carried additional mutations, suggesting a potential origin of B.1.43 in Southern California. We quantified the transmission rate of SARS-CoV-2 over time, and found evidence that the public health measures put in place in LA County to control the virus were effective at preventing transmission, but might have been undermined by the many introductions of SARS-CoV-2 into the region. Conclusion: Our work demonstrates that genome sequencing can be a powerful tool for investigating outbreaks and informing the public health response. Our results reinforce the critical need for the USA to have coordinated inter-state responses to the pandemic.


  • Multicenter Clinical Evaluation of Vitek 2 Meropenem-Vaborbactam for Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa

    by Hari P. Dwivedi, Simone Franklin, Sukantha Chandrasekaran, Omai Garner, Maria M. Traczewski, Denise Beasley, Gary W. Procop, Marion Tuohy, Deborah Wilson, Yohann Bala, et al.

    The carbapenem/beta-lactamase inhibitor meropenem-vaborbactam (MEV) used to treat complicated urinary tract infections and pyelonephritis in adults was approved in 2017 by the U.S. Food and Drug Administration (FDA). Here, we evaluated Vitek 2 MEV (bioMérieux, Durham, NC) compared to the reference broth microdilution (BMD) method.